ArticleFood & nutrition research2026
Probiotic lactic acid bacterial strains MG4693 and MG5474 alleviate atopic dermatitis by enhancing intestinal barrier integrity and modulating the immune system.
Article in Food & nutrition research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by barrier dysfunction and a Type 2 T helper cell-dominant immune response. Probiotics have emerged as promising candidates for the management of AD by modulating intestinal and systemic immune responses. Objective: This study aimed to investigate the effects of Design: AD was induced in Bagg Albino/c (BALB/c) mice by repeated topical 2,4-dinitrochlorobenzene applications, followed by the daily oral administration of MG4693 or MG5474 for 5 weeks. Skin lesions and scratching behavior in the dorsal and ear skin were evaluated. Epidermal thickness, immune cell infiltration, and levels of thymic stromal lymphopoietin (TSLP) and filaggrin were assessed by histology and immunohistochemistry. Flow cytometry was used to analyze T- and B-cell populations in lymph nodes. Intestinal barrier integrity was concurrently evaluated to investigate the involvement of the gut-skin axis. Results: Both strains significantly alleviated AD symptoms, reducing epidermal hyperplasia, eosinophil and mast cell infiltration, and TSLP expression while restoring filaggrin. In addition, these strains modulated T- and B-cell populations in the lymph nodes, indicating an immunomodulatory effect. Discussion: Amelioration of AD symptoms appears to be mediated by enhanced intestinal barrier integrity and attenuation of Type 2 T helper cell-mediated inflammatory responses. Conclusion: MG4693 and MG5474 attenuated AD pathology by improving intestinal barrier function and modulating systemic immune responses. They demonstrated potential as probiotic candidates to manage AD by targeting the gut-skin axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.